决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:CD70 CAR T cells in AML: Form follows function.
采用多模态方法开发用于急性髓系白血病的新型 CD70 靶向嵌合抗原受体(CAR)T 细胞,Leick 等。
Leick等采用多模式方法开发靶向CD70的新型嵌合抗原受体(CAR)T细胞治疗急性髓系白血病;其报告的协同策略同时改造CAR-T细胞构建体并增强白血病抗原表达,以改善CAR-T细胞功能。
Using a multimodal approach toward developing a new CD70-targeted Chimeric antigen receptor (CAR) T cell in acute myeloid leukemia, Leick et al. 1 report on their synergetic strategy, which incorporates both CAR T cell construct modifications with enhancement of leukemia antigen expression to improve CAR T cell functionality.
MEMBER ACCOUNT
登录成功会直接打开下一页。